This article is more than 5 years old. Information may no longer be current.
Vital Art and Science announces patent, study results for monitoring app
Click Here to Manage Email Alerts
Vital Art and Science LLC has announced a new U.S. patent for mVT, a FDA-approved monitoring app used to track progression of age-related macular degeneration and diabetic retinopathy, according to a company press release.
“The ability to catch disease changes early generally results in earlier treatment and better visual outcomes,” Mike Bartlett, president of Vital Art and Science, stated in the release. “And that’s what makes this patent and the mVT service important.”
In another press release, the company announced results from four studies analyzing the mVT app. In one study, researchers from San Francisco and Berkeley found mVT predicted which patients were at greatest risk for advanced disease. A second study from researchers at the University of London showed the stability of the app’s results.
Two additional studies supported by the National Institutes of Health showed mVT was significantly better at detecting visual improvement compared to visual acuity or letter contrast sensitivity and confirmed the reliability and accuracy of the app’s shape discrimination hyperacuity test.
“This validation will further boost prescriber confidence,” Bartlett stated in the release. “These studies demonstrate the mVT reliably screens for advancing disease and accurately measures treatment effects. And, of course, we are excited to see how we help improve patient outcomes.”